Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients

• DOI: 10.1007/s10549-011-1946-8
• Publication Date: 2012-01-21T04:21:27Z
• Authors: Xiangshan Zhao; Sameer Mirza; Alaa Alshareeda; Ying Zhang; Channabasavaiah B...; Aditya Bele; Jun Hyun Kim; Shakur Mohibi; Monica Goswami; Subodh M. Lele; William West; Fang Qiu; Ian O. Ellis; Emad A. Rakha; Andrew R. Green; Hamid Band; Vimla Band
• Keywords: Atypical Hyperplasia; Nottingham Prognostic Index; Breast carcinoma; Proliferation index

Uncontrolled proliferation is one of the hallmarks breast cancer. We have previously identified human Ecd protein (human ortholog Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter mammalian cell cycle progression, function related to its ability remove repressive effects Rb-family tumor suppressors on E2F transcription factors. Given frequent dysregulation regulatory components in cancer, we used immunohistochemistry paraffin-embedded tissues examine expression normal tissue versus representing increasing cancer progression. Initial studies smaller cohort without outcomes information showed that was barely detectable and hyperplasia breast, but high levels were detected benign hyperplasia, ductal carcinoma situ (DCIS) infiltrating (IDCs) breast. In this 104 IDC patients, positive correlation with higher grade (P = 0.04). Further analyses using larger, independent (954) confirmed these results, strong elevated histological 0.013), mitotic index 0.032), Nottingham Prognostic Index score 0.014). positively associated HER2/neu 0.002) overexpression, known marker poor prognosis Significantly, increased association shorter specific survival (BCSS) 0.008) disease-free (DFS) 0.003) overexpressing patients. Taken together, our results reveal for progression show predict poorer Her2/neu